ERAS - CIK 0001761918
Erasca, Inc. trades as ERAS and has a market capitalization of $4.11 B, making it the #1545 largest US-listed company by market value. This page tracks Erasca, Inc. through 326 SEC filings, with financial statements and metrics updated as new reports are filed.
| Filing | Type | Filed |
|---|---|---|
| SCHEDULE 13G/A | - | 2026-05-15 |
| SCHEDULE 13G/A | - | 2026-05-15 |
| Insider sale notice | 144 | 2026-05-15 |
| SCHEDULE 13G | - | 2026-05-15 |
| SCHEDULE 13G/A | - | 2026-05-15 |
| SCHEDULE 13G/A | - | 2026-05-12 |
| Quarterly report | 10-Q | 2026-05-11 |
| Major company event | 8-K | 2026-05-11 |
Erasca to Present at the Jefferies Global Healthcare Conference
ERAS-0015, a potentially best-in-class pan-RAS molecular glue, is being evaluated in combination with pembrolizumab
Erasca to Present at the Bank of America Securities Health Care Conference
Robust monotherapy efficacy in KRAS G12X NSCLC: 62% uORR in 2L+ and 75% uORR in post-ICI/platinum 2/3L at 16-32 mg QD PAD, and 64% uORR in 2L+ at 24-32 mg QD RDE
Conference call and live webcast today at 4:30 PM Eastern Time
The largest companies sharing Erasca, Inc.'s SEC industry classification (pharmaceutical preparations).
Erasca, Inc. (ERAS) has a market capitalization of $4.11 B as of 2026-06-10, ranking #1545 among US-listed companies.
In its latest fiscal year Erasca, Inc. reported a net loss of $124.55M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.